Amit Khurana, a market expert, has provided insights into recent corporate and regulatory developments in the Indian market. He describes Sun Pharma's acquisition as structurally strong, emphasizing that the primary challenge lies in managing the associated debt. Additionally, the cancellation of Paytm Payments Bank's license is expected to have limited impact on its core business operations. Banking sector earnings remain stable with potential for growth, whereas non-banking financial companies (NBFCs) are experiencing stretched valuations. Khurana also identifies consumption and select sectors as areas presenting investment opportunities within the current market context. Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma's acquisition is seen as strategically sound, though debt requires careful management.